Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | IRS1 | P35568 | 1/20 | 0.35 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949726 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL9030971 | 0.76 | BAZ2B (0.43) | HPGDALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL26239658 | 0.73 | ALDH1A1 (0.62) | PPARAPPARGHPGDALDH1A1HSD17B10 | |
| SCHEMBL11878553 | 0.71 | SMN1; SMN2 (0.46) | PPARGHPGDALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL15723417 | 0.70 | ALDH1A1 (0.57) | HPGDALDH1A1HSD17B10AKT1IRS1 | |
| SCHEMBL30003253 | 0.69 | NR4A1 (0.45) | PPARAPPARGHPGDNR4A1GPR84 | |
| SCHEMBL7685494 | 0.69 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL7677963 | 0.69 | LMNA (0.38) | ALDH1A1NR4A1SMN1; SMN2HTTCYP4F2 | |
| SCHEMBL9523313 | 0.68 | ALDH1A1 (0.62) | PPARAPPARGHPGDALDH1A1HSD17B10 | |
| SCHEMBL7243687 | 0.68 | ALDH1A1 (0.62) | PPARAPPARGHPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | PPARA 1357/4885PPARG 1481/4885HPGD 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.